STipe Therapeutics, an early stage Biotech company spun out from University of Aarhus, focus on harnessing the immune system to battle cancer. The company has developed first in class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major drivers of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds that modulates the tumor microenvironment, ensuring secretion of type I IFN and T-cell recruitment cytokines.
Currently, the immuno-oncology field major goal is to turn cold tumors into hot, supporting the efficacy of checkpoint inhibitors. In this regard, STipe Therapeutics can preactivate the innate immune system to rapidly detect even small amount of tumor-DNA and induces a synergistic immune response making cold tumors into hot tumors. With a solid safety profile that prohibit systemic immune activation, STipe Therapeutics will in combination with other IO drugs be able to elevate efficacy of current cancer treatments.